Sfoglia per Autore
COMPARISON OF CEA, MCA, CA 15-3, CA 27-29 IN FOLLOW UP AND MONITORING THERAPEUTIC RESPONSE IN BREAT CANCER PATIENTS
1999 Lauro, Salvatore; Trasatti, Luciana; Bordin, F; Lanzetta, G; Bria, E; Gelibter, A; Reale, Mg; Vecchione, Aldo
CA 72-4, CA 19-9 and CEA in monitoring adjuvant and metastatic colorectal cancer
2000 Bria, E.; Trasatti, L.; Gelibter, A.; Larosa, G.; Marchei, G. G.; Lauro, Salvatore; Reale, M. G.; Vecchione, A.; Frati, Luigi
CA 242 in colo-rectal and pancreatic cancer
2000 Trasatti, L.; Bria, E.; Gelibter, A.; Larosa, G.; Lauro, Salvatore; Reale, M. G.; Vecchione, A.; Frati, Luigi
Malignant bronchial Abrikossoff's tumor and small cell lung cancer: A case report and review
2001 Lauro, Salvatore; Trasatti, Luciana; Bria, E.; Gelibter, A.; Larosa, G.; Vecchione, Aldo
New approaches to prevent intestinal toxicity of irinotecan-based regimens
2004 Andrea, Alimonti; Gelibter, ALAIN JONATHAN; Ida, Pavese; Francesco, Satta; Francesco, Cognetti; Gianluigi, Ferretti; Rasio, Debora; Aldo, Vecchione; Mario Di Palma,
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: A pooled analysis of the randomised trials
2006 Ferretti, G.; Bria, E.; Giannarelli, D.; Felici, A.; Papaldo, P.; Fabi, A.; Di Cosimo, S.; Ruggeri, E. M.; Milella, M.; Ciccarese, M.; Cecere, F. L.; Gelibter, A.; Nuzzo, C.; Cognetti, F.; Terzoli, E.; Carlini, P.
Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy? [5]
2006 Gelibter, A. J.; Lonardi, S.; Di Segni, S.; Fontana, A.; Loupakis, F.; Cognetti, F.; Labianca, R.
Old age: Biologic versus chronologic [15]
2007 Gelibter, A. J.; Di Segni, S.; Zeuli, M.; Milella, M.; Ferretti, G.; Nuzzo, C.; Cognetti, F.
Aromatase inhibitors in post-menopausal metastatic breast carcinoma
2007 Carlini, P.; Bria, E.; Giannarelli, D.; Felici, A.; Papaldo, P.; Fabi, A.; Ruggeri, E. M.; Milella, M.; Nuzzo, C.; Cecere, F. L.; Gelibter, A.; Pino, M. S.; Nistico, C.; Cuppone, F.; Metro, G.; Terzoli, E.; Cognetti, F.; Ferretti, G.
Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress? A meta-analysis of 20 phase 3 trials
2007 Bria, E.; Milella, M.; Gelibter, A.; Cuppone, F.; Pino, M. S.; Ruggeri, E. M.; Carlini, P.; Nistico, C.; Terzoli, E.; Cognetti, F.; Giannarelli, D.
Sequential chemotherapy in nonsmall-cell lung cancer: Cisplatin and gemcitabine followed by docetaxel
2007 Ceribelli, A.; Pino, M. S.; Gelibter, A. J.; Milella, M.; Cecere, F. L.; Caterino, M.; Facciolo, F.; Mirri, A.; Cognetti, F.
Bevacizumab: One treatment for all the seasons? [5]
2008 Gelibter, A. J.; Zeuli, M.; Cognetti, F.; Di Segni, S.
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors. an important role for mutations in minor clones
2009 Marchetti, Antonio; Milella, Michele; Felicioni, Lara; Cappuzzo, Federico; Irtelli, Luciana; Del Grammastro, Maela; Sciarrotta, Mariagrazia; Malatesta, Sara; Nuzzo, Carmen; Finocchiaro, Giovanna; Perrucci, Bruno; Carlone, Donatella; Gelibter, Alain J; Ceribelli, Anna; Mezzetti, Andrea; Iacobelli, Stefano; Cognetti, Francesco; Buttitta, Fiamma
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers
2009 Pino, M. S.; Milella, M.; Gelibter, A.; Sperduti, I.; De Marco, S.; Nuzzo, C.; Bria, E.; Carpanese, Livio; Ruggeri, E. M.; Carlini, P.; Cognetti, F.
Fixed-dose-rate gemcitabine. A viable first-line treatment option for advanced pancreatic and biliary tract cancer
2010 Milella, M.; Gelibter, A. J.; Pino, MARIA SIMONA; Bossone, G.; Marolla, P.; Sperduti, I.; Cognetti, F.
Emerging pathways and future targets for the molecular therapy of pancreatic cancer
2011 Vaccaro, V.; Melisi, D.; Bria, E.; Cuppone, F.; Ciuffreda, L.; Pino, M. S.; Gelibter, A.; Tortora, G.; Cognetti, F.; Milella, M.
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment. A meta-analysis
2011 Bria, E.; Milella, M.; Cuppone, F.; Novello, Sebastiano; Ceribelli, A.; Vaccaro, V.; Sperduti, I.; Gelibter, A.; Scagliotti, G. V.; Cognetti, F.; Giannarelli, D.
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy
2012 Milella, M.; Nuzzo, C.; Bria, E.; Sperduti, I.; Visca, P.; Buttitta, F.; Antoniani, B.; Merola, R.; Gelibter, A.; Cuppone, F.; D'Alicandro, V.; Ceribelli, A.; Rinaldi, M.; Cianciulli, A.; Felicioni, L.; Malatesta, S.; Marchetti, A.; Mottolese, Marcella.; Cognetti, F.
Molecular and genetic bases of pancreatic cancer
2012 Vaccaro, V.; Gelibter, A.; Bria, E.; Iapicca, P.; Cappello, P.; Di Modugno, F.; Pino, M. S.; Nuzzo, C.; Cognetti, F.; Novelli, F.; Nistico, P.; Milella, M.
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy
2013 Vari, S.; Pilotto, S.; Maugeri Sacca`, M.; Ciuffreda, L.; Cesta Incani, U.; Falcone, I.; DEL CURATOLO, Anais; Ceribelli, A.; Gelibter, A.; De Maria, R.; Tortora, G.; Cognetti, F.; Bria, E.; Milella†, M.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
COMPARISON OF CEA, MCA, CA 15-3, CA 27-29 IN FOLLOW UP AND MONITORING THERAPEUTIC RESPONSE IN BREAT CANCER PATIENTS | 1999 | Lauro, Salvatore; Trasatti, Luciana; Bordin, F; Lanzetta, G; Bria, E; Gelibter, A; Reale, Mg; Vecchione, Aldo | |
CA 72-4, CA 19-9 and CEA in monitoring adjuvant and metastatic colorectal cancer | 2000 | Bria, E.; Trasatti, L.; Gelibter, A.; Larosa, G.; Marchei, G. G.; Lauro, Salvatore; Reale, M. G.; Vecchione, A.; Frati, Luigi | |
CA 242 in colo-rectal and pancreatic cancer | 2000 | Trasatti, L.; Bria, E.; Gelibter, A.; Larosa, G.; Lauro, Salvatore; Reale, M. G.; Vecchione, A.; Frati, Luigi | |
Malignant bronchial Abrikossoff's tumor and small cell lung cancer: A case report and review | 2001 | Lauro, Salvatore; Trasatti, Luciana; Bria, E.; Gelibter, A.; Larosa, G.; Vecchione, Aldo | |
New approaches to prevent intestinal toxicity of irinotecan-based regimens | 2004 | Andrea, Alimonti; Gelibter, ALAIN JONATHAN; Ida, Pavese; Francesco, Satta; Francesco, Cognetti; Gianluigi, Ferretti; Rasio, Debora; Aldo, Vecchione; Mario Di Palma, | |
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: A pooled analysis of the randomised trials | 2006 | Ferretti, G.; Bria, E.; Giannarelli, D.; Felici, A.; Papaldo, P.; Fabi, A.; Di Cosimo, S.; Ruggeri, E. M.; Milella, M.; Ciccarese, M.; Cecere, F. L.; Gelibter, A.; Nuzzo, C.; Cognetti, F.; Terzoli, E.; Carlini, P. | |
Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy? [5] | 2006 | Gelibter, A. J.; Lonardi, S.; Di Segni, S.; Fontana, A.; Loupakis, F.; Cognetti, F.; Labianca, R. | |
Old age: Biologic versus chronologic [15] | 2007 | Gelibter, A. J.; Di Segni, S.; Zeuli, M.; Milella, M.; Ferretti, G.; Nuzzo, C.; Cognetti, F. | |
Aromatase inhibitors in post-menopausal metastatic breast carcinoma | 2007 | Carlini, P.; Bria, E.; Giannarelli, D.; Felici, A.; Papaldo, P.; Fabi, A.; Ruggeri, E. M.; Milella, M.; Nuzzo, C.; Cecere, F. L.; Gelibter, A.; Pino, M. S.; Nistico, C.; Cuppone, F.; Metro, G.; Terzoli, E.; Cognetti, F.; Ferretti, G. | |
Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress? A meta-analysis of 20 phase 3 trials | 2007 | Bria, E.; Milella, M.; Gelibter, A.; Cuppone, F.; Pino, M. S.; Ruggeri, E. M.; Carlini, P.; Nistico, C.; Terzoli, E.; Cognetti, F.; Giannarelli, D. | |
Sequential chemotherapy in nonsmall-cell lung cancer: Cisplatin and gemcitabine followed by docetaxel | 2007 | Ceribelli, A.; Pino, M. S.; Gelibter, A. J.; Milella, M.; Cecere, F. L.; Caterino, M.; Facciolo, F.; Mirri, A.; Cognetti, F. | |
Bevacizumab: One treatment for all the seasons? [5] | 2008 | Gelibter, A. J.; Zeuli, M.; Cognetti, F.; Di Segni, S. | |
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors. an important role for mutations in minor clones | 2009 | Marchetti, Antonio; Milella, Michele; Felicioni, Lara; Cappuzzo, Federico; Irtelli, Luciana; Del Grammastro, Maela; Sciarrotta, Mariagrazia; Malatesta, Sara; Nuzzo, Carmen; Finocchiaro, Giovanna; Perrucci, Bruno; Carlone, Donatella; Gelibter, Alain J; Ceribelli, Anna; Mezzetti, Andrea; Iacobelli, Stefano; Cognetti, Francesco; Buttitta, Fiamma | |
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers | 2009 | Pino, M. S.; Milella, M.; Gelibter, A.; Sperduti, I.; De Marco, S.; Nuzzo, C.; Bria, E.; Carpanese, Livio; Ruggeri, E. M.; Carlini, P.; Cognetti, F. | |
Fixed-dose-rate gemcitabine. A viable first-line treatment option for advanced pancreatic and biliary tract cancer | 2010 | Milella, M.; Gelibter, A. J.; Pino, MARIA SIMONA; Bossone, G.; Marolla, P.; Sperduti, I.; Cognetti, F. | |
Emerging pathways and future targets for the molecular therapy of pancreatic cancer | 2011 | Vaccaro, V.; Melisi, D.; Bria, E.; Cuppone, F.; Ciuffreda, L.; Pino, M. S.; Gelibter, A.; Tortora, G.; Cognetti, F.; Milella, M. | |
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment. A meta-analysis | 2011 | Bria, E.; Milella, M.; Cuppone, F.; Novello, Sebastiano; Ceribelli, A.; Vaccaro, V.; Sperduti, I.; Gelibter, A.; Scagliotti, G. V.; Cognetti, F.; Giannarelli, D. | |
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy | 2012 | Milella, M.; Nuzzo, C.; Bria, E.; Sperduti, I.; Visca, P.; Buttitta, F.; Antoniani, B.; Merola, R.; Gelibter, A.; Cuppone, F.; D'Alicandro, V.; Ceribelli, A.; Rinaldi, M.; Cianciulli, A.; Felicioni, L.; Malatesta, S.; Marchetti, A.; Mottolese, Marcella.; Cognetti, F. | |
Molecular and genetic bases of pancreatic cancer | 2012 | Vaccaro, V.; Gelibter, A.; Bria, E.; Iapicca, P.; Cappello, P.; Di Modugno, F.; Pino, M. S.; Nuzzo, C.; Cognetti, F.; Novelli, F.; Nistico, P.; Milella, M. | |
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy | 2013 | Vari, S.; Pilotto, S.; Maugeri Sacca`, M.; Ciuffreda, L.; Cesta Incani, U.; Falcone, I.; DEL CURATOLO, Anais; Ceribelli, A.; Gelibter, A.; De Maria, R.; Tortora, G.; Cognetti, F.; Bria, E.; Milella†, M. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile